Jefferies Global Healthcare Conference
Logotype for Valneva SE

Valneva (VLA) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Valneva SE

Jefferies Global Healthcare Conference summary

16 Nov, 2026

Lyme disease program and regulatory path

  • Phase III efficacy was 73.2%; the primary analysis narrowly missed its prespecified confidence-interval threshold, while a second prespecified analysis including one additional placebo case cleared it. The safety profile was described as excellent.

  • EMA review clearance was completed and the application submitted and accepted; a Health Canada submission followed. Pfizer is leading ongoing FDA discussions on the BLA data package and post-marketing requirements.

  • The proposed U.S. licensure package combines the totality of clinical evidence, including a correlate-of-risk analysis linking immunogenicity to Lyme cases, case reviews over time and booster data, plus risk-benefit and health-economic analyses.

  • BLA timing shifted as FDA discussions continue on evidence and post-marketing requirements, which Lingelbach said FDA expects resolved before submission. He hoped for submission before Christmas 2026; delay could risk losing a commercial year due to Lyme seasonality.

  • A VRBPAC meeting is assumed; Lingelbach expressed confidence in a positive outcome, with risk-benefit, health-economic benefit and the totality of evidence expected to be central. No additional FDA study was anticipated.

Lyme commercial outlook

  • European licensure remains expected in fall 2027, with a possible launch in key countries that fall; Pfizer’s tick-disease and TBE commercial capabilities were cited as potential support for a launch.

  • In Europe, an initial launch phase may precede final vaccine recommendations, which can take time; reimbursement in some EU countries was discussed as a 9–12-month process.

  • Pfizer has publicly projected annual sales north of $1B; market analyses cited a $1B–$3B opportunity. High-risk populations were stated as more than 200M in Europe and 80M–90M in the U.S.

Shigella and pipeline priorities

  • The adult controlled human infection model met its primary endpoint, and the infant study showed significant anti-LPS IgG increases across four serotypes; the challenge model worked and immunogenicity correlated with efficacy.

  • Shigella responses were inconsistent across participants, indicating a need to optimize dose and schedule. Studies are being planned but will not start until there is greater Lyme clarity and funding certainty; progression in adults and children could resume thereafter.

  • Shigella could advance to its next development stage in late 2027. Clinical entry for EBV has been slowed; the EBV asset was described as differentiated, with potential to explore enteric combination vaccines.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Valneva